The Boards of Standard Life plc ("Standard Life") and Aberdeen Asset Management PLC ("Aberdeen") are pleased to announce that they have reached agreement on the terms of a recommended all-share merger of Standard Life and Aberdeen, to be effected by means of a court-sanctioned scheme of arrangement between Aberdeen and the Aberdeen Shareholders under Part 26 of the Companies Act 2006 (the "Merger"). The Combined Group will in due course be branded to incorporate the names of both Standard Life and Aberdeen.
Under the terms of the Merger, holders of Aberdeen Shares will be entitled to receive:
0.757 New Shares in exchange for each Aberdeen Share
Based on this exchange ratio (the "Exchange Ratio") and the Closing Price of 378.5 pence per Standard Life Share on 3 March 2017 (being the last Business Day prior to the date of this Announcement), the Merger values each Aberdeen Share at 286.5 pence and Aberdeen's existing issued ordinary share capital at approximately £3.8 billion.
Following completion of the Merger, Aberdeen Shareholders would own approximately 33.3 per cent. and Standard Life Shareholders would own approximately 66.7 per cent. of the Combined Group on a diluted basis.
Compelling Strategic and Financial Rationale
The Merger has a compelling strategic and financial rationale through combining Standard Life's and Aberdeen's complementary strengths to create a world class investment group.
The Boards of Standard Life and Aberdeen believe that the Merger will:
The Combined Group
The Combined Group will be headquartered in Scotland.
The Combined Group will draw on its broad expertise and harness the talent in both companies to optimise the benefits for clients and shareholders.
Following completion of the Merger:
Under the terms of the Merger, Standard Life and Aberdeen have agreed that:
Further details of the arrangements in respect of dividends are set out in paragraph 6 below.
The Aberdeen Recommending Directors, who have been so advised by J.P. Morgan Cazenove and Credit Suisse as to the financial terms of the Merger, consider the terms of the Merger to be fair and reasonable. Credit Suisse is providing independent financial advice to the Aberdeen Recommending Directors for the purposes of Rule 3 of the City Code. In providing their financial advice to the Aberdeen Recommending Directors, J.P. Morgan Cazenove and Credit Suisse have taken into account the commercial assessments of the Aberdeen Recommending Directors.
Accordingly, the Aberdeen Recommending Directors intend unanimously to recommend that Aberdeen Shareholders vote in favour of the Scheme at the Court Meeting and the resolutions relating to the Merger at the Aberdeen General Meeting (or in the event that the Merger is implemented by way of an Offer, to accept or procure acceptance of such Offer) as the Aberdeen Recommending Directors who hold Aberdeen Shares have irrevocably undertaken to do or procure in respect of their own beneficial holdings of 2,315,275 Aberdeen Shares in aggregate and representing approximately 0.2 per cent. of Aberdeen's issued share capital on 3 March 2017 (being the last Business Day prior to the release of this Announcement). Further details of these irrevocable undertakings are set out in Appendix 3 to this Announcement.
Akira Suzuki, a non-executive director of Aberdeen, is also managing executive officer of MUTB. MUTB has given a non-binding statement of support in respect of the Merger in its capacity as shareholder and ongoing business partner. In view of Akira Suzuki's position within MUTB and MUTB's interest in Aberdeen, Akira Suzuki has recused himself from the Board of Aberdeen in respect of all matters relating to the Merger.
As a result of its size, the Merger constitutes a Class 1 transaction for Standard Life for the purposes of the Listing Rules. Accordingly Standard Life will be required to seek the approval of the Standard Life Shareholders for the Merger at the Standard Life General Meeting. The Merger will also be conditional on the approval of the Standard Life Shareholders of the issuance of the New Shares at the Standard Life General Meeting. The Standard Life Directors consider the Merger to be in the best interests of Standard Life and the Standard Life Shareholders as a whole and intend unanimously to recommend that Standard Life Shareholders vote in favour of all of the resolutions to be proposed at the Standard Life General Meeting which will be convened in connection with the Merger, as they have irrevocably undertaken to do, or procure, in respect of their own beneficial holdings of 3,455,242 Standard Life Shares representing, in aggregate, approximately 0.2 per cent. of Standard Life's ordinary share capital in issue on 3 March 2017, being the last Business Day prior to the release of this Announcement.
The Standard Life Directors have received financial advice from Goldman Sachs International in relation to the Merger. In providing their advice to the Standard Life Directors, Goldman Sachs International has relied upon the Standard Life Directors' commercial assessment of the Merger.
Statements of Support
Standard Life and Aberdeen have received non-binding statements of support to vote in favour of the Scheme from each of MUTB and Lloyds, in respect of shares representing, in aggregate, approximately 27 per cent. of Aberdeen's existing issued ordinary share capital on 3 March 2017 (being the last Business Day prior to the release of this Announcement).
Further details of these statements of support are set out at paragraph 15 and Appendix 3 to this Announcement.
It is intended that the Merger will be implemented by way of a court-sanctioned scheme of arrangement between Aberdeen and the Aberdeen Shareholders under Part 26 of the Companies Act 2006, further details of which are contained in the full text of this Announcement and which will be set out in the Scheme Document. However, Standard Life reserves the right, with the consent of the Panel and Aberdeen or, in certain circumstances, without the consent of Aberdeen, to implement the Merger by way of a takeover offer (as defined in Part 28 of the Companies Act 2006), in accordance with the terms of the Cooperation Agreement.
The Merger will be subject to the Conditions and certain further terms set out in Appendix 1 to this Announcement and to the full terms and conditions which will be set out in the Scheme Document, including the approval of the Scheme by the Scheme Shareholders, the sanction of the Scheme by the Court and the approval of Standard Life Shareholders. The Conditions include the receipt of various antitrust approvals and other regulatory consents as further described in Part A of Appendix 1 to this Announcement.
The Scheme Document will include full details of the Scheme, together with notices of the Court Meeting and the Aberdeen General Meeting and the expected timetable, and will specify the action to be taken by Scheme Shareholders. It is expected that the Scheme Document will be despatched to Aberdeen Shareholders in early May 2017. For the purposes of paragraph 3(a) of Appendix 7 of the City Code and with the agreement of the Aberdeen Directors, the Panel has consented to this arrangement.
It is expected that the Prospectus, containing information about the New Shares, will be published at the same time as the Scheme Document is posted to Aberdeen Shareholders. It is also expected that the Circular, containing details of the Merger and notice of the Standard Life General Meeting, will be posted to Standard Life Shareholders at the same time as the Scheme Document is posted to Aberdeen Shareholders, with the Standard Life General Meeting being held at or around the same time as the Aberdeen Meetings.
The Scheme is expected to become effective in the third quarter of 2017, subject to the satisfaction or waiver of the Conditions and certain further terms set out in Appendix 1 to this Announcement.
"We have always been clear that it is Standard Life's ambition to become a world-class investment company and that this would be achieved through continued investment in diversification and growth, coupled with a sharp focus on financial discipline. We are therefore delighted that this announcement marks another important step towards achieving that ambition. The combination of our businesses will create a formidable player in the active asset management industry globally. We strongly believe that we can build on the strength of the existing Standard Life business by combining with Aberdeen to create one of the largest active investment managers in the world and deliver significant value for all of our stakeholders."
"We believe this merger is excellent for our clients, bringing together the strong and highly complementary investment capabilities of each firm with a breadth and depth of talent unrivalled amongst UK active managers and positioning the business to meet the evolving needs of clients and customers. This merger brings financial strength, diversity of customer base and global reach to ensure that the enlarged business can compete effectively on the global stage."
"This merger brings together two fine companies and I'm greatly honoured to be asked to chair the combination. I look forward to welcoming our new colleagues. We will be successful as long as we continue to put our clients. customers, employees and good governance at the heart of what we do."
"The strategic fit is compelling and creates a business with minimal client overlap and which is diversified by revenues, asset class and distribution channel. The combination will result in a material enhancement to earnings and this, coupled with a strong balance sheet, will facilitate significant investment in the business to support growth, innovation and a progressive dividend policy."